anti-fcrn monoclonal antibody imvt-1402
anti-fcrn monoclonal antibody imvt-1402: developed by 2 companies · 7 clinical trials tracked.
anti-fcrn monoclonal antibody imvt-1402 evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about anti-fcrn monoclonal antibody imvt-1402, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Immunovant, Inc. (IMVT) Graves' Disease; Generalized Myasthenia Gravis; Primary Sjög… | Phase 2 |
| Roivant Sciences Ltd. (ROIV) Difficult-to-Treat Rheumatoid Arthritis, Graves' Disease, My… | Phase 2/Phase 3 |
Clinical Trials (7)
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Primary endpoint: Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Primary endpoint: Change from Baseline in clinESSDAI Score at Week 24 for IMVT-1402 Dose 1 compared to Placebo
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Primary endpoint: Percentage of participants who are euthyroid and off ATD at Week 26 (Dose 1)
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
Primary endpoint: Change from Baseline in MG-ADL Score for Antibody-positive Participants
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations
Primary endpoint: Percent change from Period 1 Baseline in Cutaneous Lupus Erythematosus Disease area and Severity Index activity (CLASI-A) score at Week 12
A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat, ACPA-Positive Rheumatoid Arthritis
Primary endpoint: Proportion of participants who maintain ACR20 response at Week 28
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Primary endpoint: Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26
Frequently asked questions
Who is developing anti-fcrn monoclonal antibody imvt-1402?
anti-fcrn monoclonal antibody imvt-1402 is being developed by Immunovant, Inc., Roivant Sciences Ltd..
How many clinical trials involve anti-fcrn monoclonal antibody imvt-1402?
BioSniper tracks 7 clinical trials involving anti-fcrn monoclonal antibody imvt-1402.